Adverse events following remdesivir administration in moderately ill COVID-19 patients - A retrospective analysis

INTRODUCTION: Remdesivir, an antiviral drug, received an emergency use authorization for treating coronavirus disease 2019 (COVID-19) patients. Though many studies have reported the safety aspects of this antiviral agent, most of them were observed in severely ill COVID-19 patients, making very less...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandham, Ravi, Eerike, Madhavi, Raj, Gerard M., Bisoi, Debasis, Priyadarshini, Rekha, Agarwal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648220/
https://www.ncbi.nlm.nih.gov/pubmed/36387660
http://dx.doi.org/10.4103/jfmpc.jfmpc_2468_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648220/
https://www.ncbi.nlm.nih.gov/pubmed/36387660
http://dx.doi.org/10.4103/jfmpc.jfmpc_2468_21

Ejemplares similares